Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

The Long Non-coding RNA Flatr Anticipates Foxp3 Expression in Regulatory T Cells.

Brajic A, Franckaert D, Burton O, Bornschein S, Calvanese AL, Demeyer S, Cools J, Dooley J, Schlenner S, Liston A.

Front Immunol. 2018 Sep 25;9:1989. doi: 10.3389/fimmu.2018.01989. eCollection 2018.

2.

JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia.

de Bock CE, Cools J.

Mol Cell Oncol. 2018 Apr 4;5(3):e1458014. doi: 10.1080/23723556.2018.1458014. eCollection 2018.

PMID:
30250904
3.

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Sep 19. doi: 10.1038/s41375-018-0241-7. [Epub ahead of print]

PMID:
30232463
4.

The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer models.

Vicente C, Stirparo R, Demeyer S, de Bock CE, Gielen O, Atkins M, Yan J, Halder G, Hassan BA, Cools J.

J Hematol Oncol. 2018 Aug 25;11(1):108. doi: 10.1186/s13045-018-0650-0.

5.

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Mentens N, Vandepoel R, Geerdens E, Radaelli E, Bornhauser BC, Kulozik AE, Meijerink JP, Bourquin JP, de Bock CE, Cools J.

Cancer Cell. 2018 Aug 13;34(2):271-285.e7. doi: 10.1016/j.ccell.2018.07.007.

6.

Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.

Baens M, Stirparo R, Lampi Y, Verbeke D, Vandepoel R, Cools J, Marynen P, de Bock CE, Bornschein S.

Eur J Immunol. 2018 Oct;48(10):1728-1738. doi: 10.1002/eji.201847597. Epub 2018 Aug 7.

7.

A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

Verboom K, Van Loocke W, Volders PJ, Decaesteker B, Avila Cobos F, Bornschein S, de Bock CE, Kalender Atak Z, Clappier E, Aerts S, Cools J, Soulier J, Taghon T, Van Vlierberghe P, Vandesompele J, Speleman F, Durinck K.

Haematologica. 2018 Jun 28. pii: haematol.2018.190587. doi: 10.3324/haematol.2018.190587. [Epub ahead of print] No abstract available.

8.

The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K.

Leukemia. 2018 Jun 21. doi: 10.1038/s41375-018-0176-z. [Epub ahead of print]

PMID:
29930300
9.

Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.

De Bie J, Demeyer S, Alberti-Servera L, Geerdens E, Segers H, Broux M, De Keersmaecker K, Michaux L, Vandenberghe P, Voet T, Boeckx N, Uyttebroeck A, Cools J.

Leukemia. 2018 Jun;32(6):1358-1369. doi: 10.1038/s41375-018-0127-8. Epub 2018 Apr 18.

10.

A Micropatterned Multielectrode Shell for 3D Spatiotemporal Recording from Live Cells.

Cools J, Jin Q, Yoon E, Alba Burbano D, Luo Z, Cuypers D, Callewaert G, Braeken D, Gracias DH.

Adv Sci (Weinh). 2018 Jan 4;5(4):1700731. doi: 10.1002/advs.201700731. eCollection 2018 Apr.

11.

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

de Bock CE, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O, Vandepoel R, Vicente C, Vanden Bempt M, Dagklis A, Geerdens E, Bornschein S, Gijsbers R, Soulier J, Meijerink JP, Heinäniemi M, Teppo S, Bouvy-Liivrand M, Lohi O, Radaelli E, Cools J.

Cancer Discov. 2018 May;8(5):616-631. doi: 10.1158/2159-8290.CD-17-0583. Epub 2018 Mar 1.

PMID:
29496663
12.

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Degryse S, Bornschein S, de Bock CE, Leroy E, Vanden Bempt M, Demeyer S, Jacobs K, Geerdens E, Gielen O, Soulier J, Harrison CJ, Constantinescu SN, Cools J.

Blood. 2018 Jan 25;131(4):421-425. doi: 10.1182/blood-2017-07-797597. Epub 2017 Nov 29.

13.

Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.

Bornschein S, Demeyer S, Stirparo R, Gielen O, Vicente C, Geerdens E, Ghesquière B, Aerts S, Cools J, de Bock CE.

Leukemia. 2018 Apr;32(4):941-951. doi: 10.1038/leu.2017.328. Epub 2017 Nov 20.

14.

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Mar;32(3):788-800. doi: 10.1038/leu.2017.276. Epub 2017 Aug 30. Erratum in: Leukemia. 2018 Sep 19;:.

15.

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.

Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, de Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K.

Leukemia. 2018 Mar;32(3):809-819. doi: 10.1038/leu.2017.225. Epub 2017 Jul 24.

16.

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.

van der Krogt JA, Bempt MV, Ferreiro JF, Mentens N, Jacobs K, Pluys U, Doms K, Geerdens E, Uyttebroeck A, Pierre P, Michaux L, Devos T, Vandenberghe P, Tousseyn T, Cools J, Wlodarska I.

Haematologica. 2017 Sep;102(9):1605-1616. doi: 10.3324/haematol.2016.146571. Epub 2017 Jun 28.

17.

Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas.

Przybyl J, Kowalewska M, Quattrone A, Dewaele B, Vanspauwen V, Varma S, Vennam S, Newman AM, Swierniak M, Bakuła-Zalewska E, Siedlecki JA, Bidzinski M, Cools J, van de Rijn M, Debiec-Rychter M.

JCI Insight. 2017 Jun 2;2(11). pii: 94033. doi: 10.1172/jci.insight.94033. [Epub ahead of print]

18.

The genetics and molecular biology of T-ALL.

Girardi T, Vicente C, Cools J, De Keersmaecker K.

Blood. 2017 Mar 2;129(9):1113-1123. doi: 10.1182/blood-2016-10-706465. Epub 2017 Jan 23. Review.

19.

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.

Vercruysse T, De Bie J, Neggers JE, Jacquemyn M, Vanstreels E, Schmid-Burgk JL, Hornung V, Baloglu E, Landesman Y, Senapedis W, Shacham S, Dagklis A, Cools J, Daelemans D.

Clin Cancer Res. 2017 May 15;23(10):2528-2541. doi: 10.1158/1078-0432.CCR-16-1580. Epub 2016 Oct 25.

20.

Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors.

Dagklis A, Demeyer S, De Bie J, Radaelli E, Pauwels D, Degryse S, Gielen O, Vicente C, Vandepoel R, Geerdens E, Uyttebroeck A, Boeckx N, de Bock CE, Cools J.

Blood. 2016 Dec 8;128(23):2642-2654. Epub 2016 Sep 30.

21.

RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.

Gianfelici V, Chiaretti S, Demeyer S, Di Giacomo F, Messina M, La Starza R, Peragine N, Paoloni F, Geerdens E, Pierini V, Elia L, Mancini M, De Propris MS, Apicella V, Gaidano G, Testi AM, Vitale A, Vignetti M, Mecucci C, Guarini A, Cools J, Foà R.

Haematologica. 2016 Aug;101(8):941-50. doi: 10.3324/haematol.2015.139410. Epub 2016 May 5.

22.

Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia.

La Starza R, Barba G, Demeyer S, Pierini V, Di Giacomo D, Gianfelici V, Schwab C, Matteucci C, Vicente C, Cools J, Messina M, Crescenzi B, Chiaretti S, Foà R, Basso G, Harrison CJ, Mecucci C.

Haematologica. 2016 Aug;101(8):951-8. doi: 10.3324/haematol.2016.143875. Epub 2016 May 5.

23.

Generation of the Fip1l1-Pdgfra fusion gene using CRISPR/Cas genome editing.

Vanden Bempt M, Demeyer S, Mentens N, Geerdens E, De Bock CE, Wlodarska I, Cools J.

Leukemia. 2016 Sep;30(9):1913-6. doi: 10.1038/leu.2016.62. Epub 2016 Mar 8. No abstract available.

24.

Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.

Van Roosbroeck K, Ferreiro JF, Tousseyn T, van der Krogt JA, Michaux L, Pienkowska-Grela B, Theate I, De Paepe P, Dierickx D, Doyen C, Put N, Cools J, Vandenberghe P, Wlodarska I.

Genes Chromosomes Cancer. 2016 May;55(5):428-41. doi: 10.1002/gcc.22345. Epub 2016 Feb 6.

PMID:
26850007
25.

Blood disorders stepping into the limelight.

Jäger U, Chomienne C, Cools J, Smand C.

Haematologica. 2016 Feb;101(2):101-3. doi: 10.3324/haematol.2016.142018. Epub 2016 Jan 27. No abstract available.

26.

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.

Wandinger SK, Lahortiga I, Jacobs K, Klammer M, Jordan N, Elschenbroich S, Parade M, Jacoby E, Linders JT, Brehmer D, Cools J, Daub H.

PLoS One. 2016 Jan 8;11(1):e0146100. doi: 10.1371/journal.pone.0146100. eCollection 2016.

27.

Resolutions for the New Year.

Cools J.

Haematologica. 2016 Jan;101(1):1. doi: 10.3324/haematol.2015.139352. No abstract available.

28.

The origin of relapse in pediatric T-cell acute lymphoblastic leukemia.

Vicente C, Cools J.

Haematologica. 2015 Nov;100(11):1373-5. doi: 10.3324/haematol.2015.136077. No abstract available.

29.

The genomic landscape of adult T cell leukemia/lymphoma.

Vicente C, Cools J.

Nat Genet. 2015 Nov;47(11):1226-7. doi: 10.1038/ng.3428.

PMID:
26506901
30.

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Losdyck E, Hornakova T, Springuel L, Degryse S, Gielen O, Cools J, Constantinescu SN, Flex E, Tartaglia M, Renauld JC, Knoops L.

J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.

31.

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.

Degryse S, Cools J.

J Hematol Oncol. 2015 Jul 26;8:91. doi: 10.1186/s13045-015-0192-7.

32.

Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.

Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, Lahortiga I, Elliott A, Chilton L, La Starza R, Mecucci C, Vandenberghe P, Goulden N, Vora A, Moorman AV, Soulier J, Harrison CJ, Clappier E, Cools J.

Haematologica. 2015 Oct;100(10):1301-10. doi: 10.3324/haematol.2015.130179. Epub 2015 Jul 23.

33.

Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia.

Durinck K, Van Loocke W, Van der Meulen J, Van de Walle I, Ongenaert M, Rondou P, Wallaert A, de Bock CE, Van Roy N, Poppe B, Cools J, Soulier J, Taghon T, Speleman F, Van Vlierberghe P.

Leukemia. 2015 Dec;29(12):2317-27. doi: 10.1038/leu.2015.162. Epub 2015 Jun 25.

PMID:
26108691
34.

T-ALL: Home Is where the CXCL12 Is.

de Bock CE, Cools J.

Cancer Cell. 2015 Jun 8;27(6):745-6. doi: 10.1016/j.ccell.2015.05.011.

35.

A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2).

Duval R, Bui LC, Berthelet J, Dairou J, Mathieu C, Guidez F, Dupret JM, Cools J, Chomienne C, Rodrigues-Lima F.

Sci Rep. 2015 Jun 4;5:10750. doi: 10.1038/srep10750.

36.

CD45 antigen negativity in T-lineage ALL correlates with PTPRC mutation and sensitivity to a selective JAK inhibitor.

Raponi S, Gianfelici V, Chiaretti S, Peragine N, Brugnoletti F, De Propris MS, Marinelli M, Hulselmans G, Aerts S, Geerdens E, Cools J, Foà R, Guarini A.

Br J Haematol. 2015 Dec;171(5):884-7. doi: 10.1111/bjh.13448. Epub 2015 Apr 8. No abstract available.

PMID:
25854815
37.

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.

Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, Carter DR, Cazes A, Cheung BB, De Mariano M, De Bondt A, De Brouwer S, Delattre O, Gibbons J, Janoueix-Lerosey I, Laureys G, Liang C, Marchall GM, Porcu M, Takita J, Trujillo DC, Van Den Wyngaert I, Van Roy N, Van Goethem A, Van Maerken T, Zabrocki P, Cools J, Schulte JH, Vialard J, Speleman F, De Preter K.

Clin Cancer Res. 2015 Jul 15;21(14):3327-39. doi: 10.1158/1078-0432.CCR-14-2024. Epub 2015 Mar 24.

38.

Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia.

Dagklis A, Pauwels D, Lahortiga I, Geerdens E, Bittoun E, Cauwelier B, Tousseyn T, Uyttebroeck A, Maertens J, Verhoef G, Vandenberghe P, Cools J.

Haematologica. 2015 Mar;100(3):e102-5. doi: 10.3324/haematol.2014.119248. Epub 2014 Dec 19. No abstract available.

39.

The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.

Durinck K, Wallaert A, Van de Walle I, Van Loocke W, Volders PJ, Vanhauwaert S, Geerdens E, Benoit Y, Van Roy N, Poppe B, Soulier J, Cools J, Mestdagh P, Vandesompele J, Rondou P, Van Vlierberghe P, Taghon T, Speleman F.

Haematologica. 2014 Dec;99(12):1808-16. doi: 10.3324/haematol.2014.115683. Epub 2014 Oct 24.

40.

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P.

Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9.

41.

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.

Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, Jacobs K, Geerdens E, Gianfelici V, Hulselmans G, Fiers M, Aerts S, Meijerink JP, Tousseyn T, Cools J.

Blood. 2014 Nov 13;124(20):3092-100. doi: 10.1182/blood-2014-04-566687. Epub 2014 Sep 5.

42.

Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks.

Zhao H, Thienpont B, Yesilyurt BT, Moisse M, Reumers J, Coenegrachts L, Sagaert X, Schrauwen S, Smeets D, Matthijs G, Aerts S, Cools J, Metcalf A, Spurdle A; ANECS, Amant F, Lambrechts D.

Elife. 2014 Aug 1;3:e02725. doi: 10.7554/eLife.02725.

43.

Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma.

Finalet Ferreiro J, Rouhigharabaei L, Urbankova H, van der Krogt JA, Michaux L, Shetty S, Krenacs L, Tousseyn T, De Paepe P, Uyttebroeck A, Verhoef G, Taghon T, Vandenberghe P, Cools J, Wlodarska I.

PLoS One. 2014 Jul 24;9(7):e102977. doi: 10.1371/journal.pone.0102977. eCollection 2014.

44.

RHOA mutations in peripheral T cell lymphoma.

Cools J.

Nat Genet. 2014 Apr;46(4):320-1. doi: 10.1038/ng.2937.

PMID:
24675518
45.

The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.

Noël LA, Arts FA, Montano-Almendras CP, Cox L, Gielen O, Toffalini F, Marbehant CY, Cools J, Demoulin JB.

Mol Oncol. 2014 May;8(3):728-40. doi: 10.1016/j.molonc.2014.02.003. Epub 2014 Feb 17.

46.

DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia.

Brandimarte L, La Starza R, Gianfelici V, Barba G, Pierini V, Di Giacomo D, Cools J, Elia L, Vitale A, Luciano L, Bardi A, Chiaretti S, Matteucci C, Specchia G, Mecucci C.

Haematologica. 2014 May;99(5):64-6. doi: 10.3324/haematol.2013.101725. Epub 2014 Feb 28. No abstract available.

47.

G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

Lee HK, Kim HW, Lee IY, Lee J, Lee J, Jung DS, Lee SY, Park SH, Hwang H, Choi JS, Kim JH, Kim SW, Kim JK, Cools J, Koh JS, Song HJ.

Blood. 2014 Apr 3;123(14):2209-19. doi: 10.1182/blood-2013-04-493916. Epub 2014 Feb 14.

48.

Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1.

Rouhigharabaei L, Finalet Ferreiro J, Tousseyn T, van der Krogt JA, Put N, Haralambieva E, Graux C, Maes B, Vicente C, Vandenberghe P, Cools J, Wlodarska I.

PLoS One. 2014 Jan 9;9(1):e85851. doi: 10.1371/journal.pone.0085851. eCollection 2014.

49.

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Sadovnik I, Lierman E, Peter B, Herrmann H, Suppan V, Stefanzl G, Haas O, Lion T, Pickl W, Cools J, Vandenberghe P, Valent P.

Exp Hematol. 2014 Apr;42(4):282-293.e4. doi: 10.1016/j.exphem.2013.12.007. Epub 2014 Jan 6.

50.

Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia.

Atak ZK, Gianfelici V, Hulselmans G, De Keersmaecker K, Devasia AG, Geerdens E, Mentens N, Chiaretti S, Durinck K, Uyttebroeck A, Vandenberghe P, Wlodarska I, Cloos J, Foà R, Speleman F, Cools J, Aerts S.

PLoS Genet. 2013;9(12):e1003997. doi: 10.1371/journal.pgen.1003997. Epub 2013 Dec 19.

Supplemental Content

Support Center